Pharmaceutical - Financial, Patents


Current filters:


Popular Filters

UK Patent Box changes require urgent clarification, says Withers & Rogers


Last month, Treasury Minister David Gauke gave a robust defence of the UK's Patent Box scheme, which…


UPDATE: UK agrees “Patent Box” compromise with Germany

UPDATE: UK agrees “Patent Box” compromise with Germany


Germany and the UK have agreed a joint proposal to advance the negotiations on new rules for preferential…


Joint position to grow Australia's biopharmaceutical industry

Joint position to grow Australia's biopharmaceutical industry


Trade groups AusBiotech and Medicines Australia this morning published a joint statement sent to the…

AustraliaBiotechnologyFinancialMarkets & MarketingPatentsPharmaceuticalResearch

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal


The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care…

EuropefentanylFinancialJohnson & JohnsonNeurologicalNovartisPatentsPharmaceuticalSandoz

Low level of “potentially problematic” patent settlements in EU pharma sector

Low level of “potentially problematic” patent settlements in EU pharma sector


The European Commission's report on patent settlement agreements, also referred to as “pay-for-delay”…


Teva denies claims its MS drug Copaxone profits set to slump

Teva denies claims its MS drug Copaxone profits set to slump


Israel’s Teva Pharmaceutical Industries, the world’s largest generic drugmaker, this morning strongly…

CopaxoneEuropeFinancialMylan LaboratoriesNeurologicalPatentsPharmaceuticalTeva Pharmaceutical Industries

US pharma patent settlements netted $25.5 billion in savings for health system; report


Generic pharmaceuticals launched prior to patent expiration due to a patent settlement - also called…

FinancialGenericsNorth AmericaPatentsPharmaceutical

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals


In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

Tightening health budgets on both sides of the Atlantic leading to crackdowns on patent settlements, says EIU analyst


Later this month, following an inquiry launched in 2009, the European Commission is expected to impose…

EuropeFinancialGenericsNorth AmericaPatentsPharmaceuticalPoliticsRegulation

Europe falling behind USA and China as attractive for life sciences sector


Intellectual property specialists Marks & Clerk's latest Life Sciences Report unveils the changing landscape…


Vision for "better health through research" in Australia set out in new report


Australian Minister for Health Tanya Plibersek on April 5 released the report of the McKeon Review -…


Daiichi Sankyo sets out five-year plan to overcome Olmetec patent expiry


Japanese drug major Daiichi Sankyo (TYO: 4568) has announced a new five-year Business Plan, which will…

Daiichi SankyoFinancialolmesartanOlmetecPatentsPharmaceuticalRanbaxy Laboratories

New approach to drug discovery urged by US academician


Garret FitzGerald, chairman of the Department of Pharmacology and Director of the Institute for Translational…

BiotechnologyFinancialNorth AmericaPatentsPharmaceuticalResearch

Drugmakers to continue facing growing generic competition in 2013


Last year saw the expiration of patents for several blockbuster drugs, leading to increasing generic…

AmarinFinancialForest LaboratoriesGenericsPatentsPharmaceutical

Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million


Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's…

CopaxoneFinancialGenericsLicensingPatentsPharmaceuticalResearchTeva Pharmaceutical IndustriesXenon Pharmaceuticals

Overview of Novartis' patent losses from GlobalData


Swiss drug major Novartis (NOVN: VX) is the latest victim of patent protection loss, note analysts at…


European Unitary Patent and Patent Box dominate the London patent summit


With a key meeting on the 40-year old saga of the European Single Unitary Patent scheduled for December…


Pharma vs the world: Big Pharma caught between investors and public


Big Pharma today encounters a variety of pressures from generics manufacturers, governments, patient…

FinancialGenericsGlobalMarkets & MarketingPatentsPharmaceuticalPoliticsSanofi

Merck & Co 1st-qtr earnings just beat expectations; wins Mylan patent dispute


US drug giant Merck & Co sales that global sales in the first-quarter of 2012 increased 1% to $11.7 billion,…

FinancialLegalMerck & CoMylan LaboratoriesNorth AmericaPatentsPharmaceuticalVytorinZetia

Sanofi fourth-quarter in line with forecasts; collects damages


French drug major Sanofi (Euronext: SAN) this morning reported 8.8% growth in fourth-quarter 2011 sales…

ApotexBristol-Myers SquibbFinancialGenericsLegalPatentsPharmaceuticalPlavix

Pharma industry could use a shot in the arm, says Fitch; FT views bribery settlements


2012 will be a critical year for the pharmaceutical industry, as drugmakers struggle with record patent…

FinancialLegalMarkets & MarketingPatentsPharmaceuticalResearch

Novartis cuts jobs, takes $1.22 billion charges


In anticipation of the blockbuster antihypertensive Diovan’s (valsartan) patent expiration and an…


Back to top